cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Amicus Therapeutics Inc
14 own
24 watching
Current Price
$10.84
$0.23
(2.17%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
3,575.25M
52-Week High
52-Week High
14.57000
52-Week Low
52-Week Low
9.70000
Average Volume
Average Volume
1.1M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization3,575.25M
icon52-Week High14.57000
icon52-Week Low9.70000
iconAverage Volume1.1M
iconDividend Yield--
iconP/E Ratio--
What does the Amicus Therapeutics Inc do?
Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. Its principal product is the migalastat HCl, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease, which has completed two global Phase III registration studies. The company is also developing SD-101, which is in Phase III clinical study for the treatment of the genetic connective tissue disorder epidermolysis bullosa; and AT3375 to treat Parkinson's disease. It is conducting a Phase 1/2 clinical study of ATB200-02 to investigate pompe treatment paradigm in pompe patients. The company has strategic alliance with GlaxoSmithKline plc to develop and commercialize migalastat as a monotherapy and in combination with ERT for Fabry disease. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey.
Read More
How much money does Amicus Therapeutics Inc make?
News & Events about Amicus Therapeutics Inc.
Zolmax
12 months ago
Amicus Therapeutics, Inc. (NASDAQ:FOLD Get Rating) has been assigned an average rating of Moderate Buy from the six brokerages that are currently covering the company, MarketBeat.com reports. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the ...
Globe Newswire
12 months ago
European Commission Approval of Opfolda and Commercial Launch of Pombiliti + Opfolda Anticipated in 3Q 2023 Upon Approval, Pombiliti + Opfolda will be the First Two-Component Therapy in the European Union for the Treatment of Adults Living with Late-Onset Pompe Disease PHILADELPHIA, April 26, 2023 (...
Zolmax
1 year ago
Amicus Therapeutics, Inc. (NASDAQ:FOLD Get Rating) Chairman John F. Crowley sold 6,044 shares of the firms stock in a transaction that occurred on Monday, April 17th. The stock was sold at an average price of $11.66, for a total transaction of $70,473.04. Following the sale, the chairman now owns ...
Globe Newswire
1 year ago
PHILADELPHIA, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Cowen 43rd Annual Health Care Conference in Boston, MA on Monday, March 6, 2023 at 9:50 a.m. E.T. A live audio webcast of the presentation can...
Globe Newswire
1 year ago
CHMP Adopts Positive Opinion Based Upon Complete Review of all Pre-Clinical, Clinical Studies and CMC Data CHMP Recommends Label for Long-Term Enzyme Replacement Therapy in Combination with Miglustat for both ERT-Experienced and Treatment-Nave Adults Living with Late-Onset Pompe Disease CHMP Opinion...
Frequently Asked Questions
Frequently Asked Questions
What is Amicus Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Amicus Therapeutics Inc shares?
plus_minus_icon
How can I buy Amicus Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Amicus Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Amicus Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Amicus Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Amicus Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Amicus Therapeutics Inc?
plus_minus_icon
What percentage is Amicus Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Amicus Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$10.84
$0.23
(2.17%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00